Abstract library

1750 results for "pancreatic net".
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#2293 Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET)
Introduction: While the genomic and transcriptomic landscape of low proliferating PanNET have been well studied, pathways driving aggressive WD PanNET are still unclear.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jerome Cros
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#842 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki-67 Index Predict Response to Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)
Introduction: Temozolomide (TEM) showed encouraging results in WDPNET. Decreased MGMT expression and methylation of its promoter seems to correlate with better outcome in TEM-treated glioblastomas.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Dr Jerome Cros
Authors: Cros J, Hentic O, Rebours V, Zappa M, ...
#1297 Efficacy and Safety of Targeted Agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumor (NET): Single Center Experience
Introduction: As clinical features of NET are heterogeneous, the evaluation of real-world outcomes with everolimus and sunitinib are necessary.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Cho H, Kim K, Chang H M, ...
#2207 Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study
Introduction: Specific biomarkers for predicting response and risk of recurrence after surgery for enteropancreatic neuroendocrine tumours (EP-NETs) are still lacking.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Francesca Muffatti
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof Marianne Pavel
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, ...